2019 REPORT

ACCESS, KEY TO #HOPEREALIZED

FACES OF LUNG CANCER
# TABLE OF CONTENTS

**2019 FACES OF LUNG CANCER FOREWORD**  Page 2
#HopeRealized - Access is crucial

**INTRODUCTION**  Page 3
#HopeRealized - Progress but much work remains

**Part 1** THE CHANGING PARADIGM OF LUNG CANCER IN CANADA  Page 5
#19isbetterthan17 - Highlights of 2019 lung cancer statistics

**Part 2** THE REALITY OF ACCESS IN CANADA  Page 8
#AccessinCanada
#ScreeningisCritical - Lung Cancer Screening Saves Lives and Money
#ItmightbeCancer - Getting to a Diagnosis
#MolecularTesting
#TakingcareofCanada - Lung cancer access in remote parts of Canada

**Part 3** WHO PAYS FOR CANCER?  Page 21
#Hopeinfunding - The shape of drug funding in Canada

**Part 4** CONCLUSION  Page 32
#HopefortheFuture

**Part 5** WHO WE ARE  Page 34
#LCC - Lung Cancer Canada
A little more than a decade ago, I was a 30-year-old elementary school teacher in Toronto with a full and rewarding life. Sure, I felt more tired than usual, but I put that down to overwork. Then I noticed a small lump on my collarbone. Shortly after that, I saw my general practitioner, who ordered a chest X-ray after examining me. The X-ray revealed a shadow. Next, a CT scan called for a biopsy, which led to a devastating diagnosis: I had stage III adenocarcinoma lung cancer! As anyone would be, I was stunned. Lung cancer? How was that possible? I had never smoked in my life, and like many people, I mistakenly thought that only smokers got lung cancer. Of course, I know better now. As I often say, “If you have lungs, you can get lung cancer.” In my case, the standard of care — radiation, chemotherapy, surgery — was prescribed. Two years later, my cancer progressed to stage IV non-small cell lung carcinoma with the mutated gene anaplastic lymphoma kinase (ALK). My situation had been dire before; now I was told I was terminal. However, I was able to qualify for a clinical trial of a treatment specifically targeted to ALK. I was in that trial for five years and then entered a second clinical trial for another targeted drug, which I am still in. During all this time, I have been able to live a pretty good life. I met a wonderful man and married him, and we even bought a house.

Living with lung cancer for 10 years is rare. I often call myself a unicorn. However, for there to be more unicorns like me, a lot of things are critical: newer drugs; new ways to improve screening, diagnosis, and treatment; new strategies for delivery and funding of care. But along with all that, access is key. Chemotherapy, radiation, and surgery for lung cancer are fully funded in Canadian provinces, but for rarer mutations like mine, the cost of drugs can be prohibitive and may not be entirely covered by private or public insurance plans. Also, I live in Canada’s largest city. Many people across our nation, whatever kind of lung cancer they have, are in rural areas or much smaller places, and their access to screening, diagnosis, and care is far more difficult.

So what is my wish list for the access and treatment of lung cancer in the future? Better awareness of what can cause the disease. Earlier screening and diagnostics. Essential changes to how our health systems operate such as improving access to care closer to home, fully funded take-home drugs, eliminating the disparity between small and large centres for cancer treatment. Improved cooperation between governments and pharmaceutical companies to reduce the cost of new, innovative drugs.

The 2019 Faces of Lung Cancer Report that follows looks at many of these issues in detail to offer more examples of #HopeRealized and what we need to do to improve the different aspects of access to lung cancer care and treatment. Unicorns like me don’t need to be rare.

— Anne Marie Cerato
INTRODUCTION

Anne Marie Cerato,
Dr Rosalyn Juergens and
Prof Raymond Laflamme

Photo credit – Neal Burstyn
(NTB Creative)
Lung cancer is the most commonly diagnosed cancer in Canada and is the leading cause of cancer death.

In the past years, progress in treatment has helped Anne Marie Cerato achieve her 10-year lung cancer “cancerversary,” while advances in screening have aided patients such as Debi Lascelle, who is featured later in this report and whose story was also told in the 2017 edition of the *Faces of Lung Cancer Report*.

Progress has helped the five-year survival rate for Canada’s deadliest cancer move from 17 percent to 19 percent, as reported in the Canadian Cancer Society’s Canadian Cancer Statistics 2019. Access is not universal across Canada, but access to services and treatments are key components to fighting lung cancer in Canada and increasing survival rates, particularly since almost 50 percent of lung cancer is diagnosed at a late stage. Access is complicated by Canada’s vast geography and diverse cultures, as well as by how Canada’s healthcare system is set up. Healthcare is a partnership between federal and provincial governments. Health Canada, a federal body, approves drugs, but provinces oversee the listing and administration of healthcare.

The situation is complex, especially in this era of new surgical techniques and new treatments. Treatments have modernized, but it can be argued that our healthcare system has struggled to keep up.

Lung cancer patients are further disadvantaged compared to patients with other cancers, since currently lung cancer accounts for 26 percent of all cancer deaths and yet only receives less than 7 percent of the research funding.

Access is complicated by Canadian’s vast geography and diverse cultures, as well as by how Canada’s healthcare system is set up. Healthcare is a partnership between federal and provincial governments. Health Canada, a federal body, approves drugs, but provinces oversee the listing and administration of healthcare.

The situation is complex, especially in this era of new surgical techniques and new treatments. Treatments have modernized, but it can be argued that our healthcare system has struggled to keep up.

Lung cancer patients are further disadvantaged compared to patients with other cancers, since currently lung cancer accounts for 26 percent of all cancer deaths and yet only receives less than 7 percent of the research funding.

Access is complicated by Canada’s vast geography and diverse cultures, as well as by how Canada’s healthcare system is set up. Healthcare is a partnership between federal and provincial governments. Health Canada, a federal body, approves drugs, but provinces oversee the listing and administration of healthcare.

The situation is complex, especially in this era of new surgical techniques and new treatments. Treatments have modernized, but it can be argued that our healthcare system has struggled to keep up.

Lung cancer patients are further disadvantaged compared to patients with other cancers, since currently lung cancer accounts for 26 percent of all cancer deaths and yet only receives less than 7 percent of the research funding.

We must find solutions. Access is key to #HopeRealized. In the 2019 *Faces of Lung Cancer Report*, Lung Cancer Canada’s Medical Advisory Committee follows the patient journey and examines access, inequalities in access, barriers, and examples of best practices across the country. The committee examines factors affecting patient outcomes and provides suggestions to help improve access so that all Canadians living with lung cancer have an equal chance at #HopeRealized.
PART 1

THE CHANGING PARADIGM OF LUNG CANCER IN CANADA
Every year the Canadian Cancer Society (CCS) produces a report that updates cancer statistics in Canada for incidence, mortality, and survivability. It also breaks down factors such as age, sex, and geographic location. In the 2019 CCS report, as in previous years, the leading cause of cancer death in Canada is still lung cancer.4

The statistics in Table 1 below show the picture of lung cancer in Canada in 2019. These statistics and the provincial differences (Table 2) are the starting point of our examination.

**Table 1: 2019 Canadian Lung Cancer Statistics**

<table>
<thead>
<tr>
<th>2019 Canadian Lung Cancer Statistics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cancer deaths due to lung cancer</td>
<td>1 in 4</td>
</tr>
<tr>
<td>Canadians who will be diagnosed with lung cancer in lifetime</td>
<td>1 in 15</td>
</tr>
<tr>
<td>Canadians who will die from lung cancer in lifetime</td>
<td>1 in 17</td>
</tr>
<tr>
<td>Most commonly diagnosed cancer for Canadian females</td>
<td>breast 25%, lung 14%</td>
</tr>
<tr>
<td>Mortality percentage of all cancers for Canadian females</td>
<td>lung 26%, breast 13%, colorectal 11%</td>
</tr>
<tr>
<td>Most commonly diagnosed cancer for Canadian males</td>
<td>prostate 20%, lung, 13%</td>
</tr>
<tr>
<td>Mortality percentage of all cancers for Canadian males</td>
<td>lung 25%, colorectal 12%, prostate 10%</td>
</tr>
</tbody>
</table>

Other lung cancer highlights from the CCS 2019 report include:

- The estimated five-year survival rate for lung cancer in 2019 is 19 percent, an increase of 2 percent from previous statistics. The five-year lung cancer survival rate for females is 22 percent; for males 15 percent, while the ten-year 2019 lung cancer survival rate for females is 16 percent and for males, 11 percent.
- The highest incidence rates of lung cancer for both Canadian males and females are found in Nova Scotia, New Brunswick, and Prince Edward Island (see Table 2).
- For males, lung cancer mortality rates are highest in Quebec and the Atlantic Provinces, while for females the lowest is found in Ontario, with the highest in Quebec (see Table 2).
Regional differences in incidence and mortality are able to help us identify areas of need. Overall lung cancer incidence and mortality rates are higher in Quebec and the Atlantic provinces than those in Ontario and British Columbia.

There are many reasons for differences in lung cancer rates among the provinces, some of which are due to differences in risk-factor rates. For example, Quebec has higher smoking rates, while many people in Atlantic Canada have poorer diets and lower incomes.  

Diagnostic practices and data collection methods may also differ between provinces. However, an important aspect is the availability and distance to healthcare services.

As we move forward in this report and examine the availability of healthcare services, it is important to consider their impact on health outcomes. Lung cancer survival rates, as well as statistics for incidence and mortality, provide evaluation of the progress made in the treatment and control of this devastating disease. They also indicate where more still needs to be done.

Table 2: 2019 Lung Cancer Incidence and Mortality Rates by Gender and Canadian Province*

<table>
<thead>
<tr>
<th>PROVINCE</th>
<th>MEN</th>
<th>WOMEN</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>INCIDENCE</td>
<td>MORTALITY</td>
<td>INCIDENCE</td>
<td>MORTALITY</td>
<td>INCIDENCE</td>
<td>MORTALITY</td>
</tr>
<tr>
<td>Alberta</td>
<td>60.1</td>
<td>45</td>
<td>58</td>
<td>41</td>
<td></td>
<td></td>
</tr>
<tr>
<td>British Columbia</td>
<td>54.4</td>
<td>42.9</td>
<td>53.4</td>
<td>39.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manitoba</td>
<td>70</td>
<td>49.9</td>
<td>63</td>
<td>46.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Brunswick</td>
<td>87.3</td>
<td>73.3</td>
<td>71.4</td>
<td>46.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newfoundland and Labrador</td>
<td>79.8</td>
<td>75.5</td>
<td>62.5</td>
<td>44.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>86.7</td>
<td>69.9</td>
<td>76</td>
<td>54.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ontario</td>
<td>67.5</td>
<td>47.9</td>
<td>59.6</td>
<td>36.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prince Edward Island</td>
<td>90.9</td>
<td>72.5</td>
<td>66</td>
<td>46.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quebec**</td>
<td></td>
<td>71.5</td>
<td>54.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>67.4</td>
<td>52.8</td>
<td>63.3</td>
<td>45.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Estimate rates are per 100,000 people. All estimates are from Canadian Cancer Statistics 2019, which is available at cancer.ca/statistics. Additional details on data sources and methods used to obtain these estimates are outlined in Appendix II of that publication. Cases are projected number of cancer diagnoses in 2019 based on data to 2015. Deaths are projected number of cancer deaths in 2019 based on data to 2015. **Quebec estimates for incidence are not included because a different projection method was used for Quebec than the other provinces, meaning the estimates are not comparable.
PART 2

THE REALITY OF ACCESS IN CANADA
A diagnosis of lung cancer takes a patient and his or her family on a journey no one is ever able to prepare for. Inevitably, patients ask, “What are my chances?” or “Will I survive?”

Currently, for the majority of Canadians diagnosed with lung cancer, a positive answer to these questions is handicapped by a late diagnosis. Almost 50 percent of lung cancer is diagnosed at stage IV, an incurable stage. This compares to just under 5 percent of breast cancer and 20 percent of colorectal cancer diagnosed at stage IV (see Figure 1 below).

Figure 1 - Percentages of Stage Diagnosis for Lung and Bronchus, Breast, and Colorectal Cancers

Analysis by: Health Statistics Division, Statistics Canada
Data Source: Canadian Cancer Registry database at Statistics Canada

*Excludes Quebec  †Includes cases diagnosed in people aged 18-79 years
Early diagnosis is critical to improved survivorship and screening is key. Unlike other cancer-screening programs, current lung cancer screening guidelines only target those at highest risk. The Canadian Task Force for Preventative Health currently recommends lung cancer screening using low dose CT (LDCT) “for adults aged 55–74 years with at least a 30 pack-year smoking history who currently smoke or quit less than 15 years ago.” Annual screening up to three consecutive times is recommended. The evidence is strong. The Dutch-Belgium NELSON trial analysis of 10 years of follow-up showed a significant 25 percent reduction in lung cancer mortality in men and up to 61 percent reduction in mortality in women compared to those who were not screened. At this year’s World Conference on Lung Cancer, Canadian researcher Dr Stephan Lam presented data to show that the Canadian screening model detected more cancers than the screening model used in the United States.

Not only does lung cancer screening save lives, it also saves the system money. Canadian physician, Dr Sonya Cressman’s research indicates the mean per-person cost of treating lung cancer with curative surgery was $33,344 over two years. This was significantly lower than the mean per-person cost of $47,792 to treat advanced stage lung cancer with chemotherapy, radiotherapy, or supportive care alone. The difference is even larger if targeted therapies or immunotherapies are employed.

Yet despite this evidence, as shown in Table 3 below, no province in Canada has adopted a publicly funded lung cancer screening program — in fact, many provinces do not even have pilot programs. The evidence is clear: lack of access to lung cancer screening programs will continue to act as a barrier to early diagnosis. As the cost of cancer treatments continues to rise, implementing lung cancer screening across the country would be both morally and fiscally responsible.

Hand in hand with screening programs are smoking-cessation programs. Smoking-cessation support and clinics as well as nicotine-replacement programs are available but are limited in some Canadian provinces (see Table 3).

Smoking-cessation counselling and therapies can be efficiently incorporated into screening programs, and the infrastructure needs to become more prevalent in all provinces and territories, whether through municipal public health programs or provincial initiatives.
Presented at the World Lung Conference in Toronto this past fall, the Dutch-Belgium NELSON-trial, which is a population-based randomized control trial comparing CT screening with no screening in ever smokers between the age of 50 to 74 years who have smoked at least 15 cigarettes a day for 25 years or more or at least 10 cigarettes a day for 30 years or more and have smoked within 10 years. Between 2004 and 2006, the study enrolled 15,822 participants. The CT screening received a baseline CT and three additional screenings at intervals of 1, 2 and 2.5 years. Analysis at 10 years of follow-up showed a significant 26% reduction in lung cancer mortality in men and up to 61% reduction in mortality in women compared to the no screening group.

With two global, large randomized trials demonstrating significant mortality reduction, we now have clear evidence to support the implementation of lung cancer screening similar to breast and colorectal screening that save the lives of countless individuals.

New research projects are very important in the area of lung cancer. Despite being Canada’s deadliest cancer killer, lung cancer receives some of the lowest funding for research compared to other cancers.

**LUNG CANCER CANADA BELIEVES**

All provinces and territories need to adopt consistent screening programs. Breast cancer and cervical cancer screening programs are widespread, but for lung cancer there is the need for comprehensive low-dose CT screening programs in selected populations, which should be linked with smoking-cessation services. Infrastructure needs to be put in place to provide patients with positive screening tests and appropriate diagnostic and follow-up services.
DEBI LASCELLE
Faces of Lung Cancer Patient Story

Debi was profiled in our 2017 Faces of Lung Cancer Report. Now 62 years old, Debi was first diagnosed with lung cancer nine years ago.

Back in 2010, she saw a newspaper advertisement for a study of people who were smokers or ex-smokers but held off applying, carrying the clipping around for a few months. When she did contact the Ottawa General Hospital, which was participating in the Pan-Canadian Early Lung Cancer Detection Study in eight cities across the country, she qualified and was able to take part in the study.

A CT scan revealed a lesion in her right lung, a biopsy was ordered, and the diagnosis came back that she had stage IA lung cancer. A PET scan and MRI determined that there was no other cancer in her body, and on Valentine’s Day 2011, she underwent a lobectomy to remove a 13-millimetre adenocarcinoma from her right lung.

Debi’s been cancer-free for eight years, takes no medications, and says she continues her yoga and works out as much, perhaps more, than she did before her diagnosis. “Of course,” she quickly admits, “I won’t be hiking up Mount Kilimanjaro.” Still, she insists (and our medical advisory committee agree), without access to the early screening she had, she would likely not be here today. The study that Debi took part in, along with other screening studies, have shown that if lung cancer is discovered early enough, 70 percent of patients can be diagnosed at stage I or II.

When asked what she would like to see for the future of lung cancer treatment, she replies, “I hope that every Canadian province and territory adopts an organized, regular early screening program. We do it for breast, and colon cancer, so why not lung cancer? What’s more, early screening, detection, and treatment of lung cancer saves money in the long run.”

A former provincial court reporter, Debi is now retired and lives with her husband, John, who she’s been married to for almost 30 years. After everything that she’s been through, what does she have to say about her overall experience with the health system? She ponders that question for a moment, then affirms, “It’s been very positive from the get-go. I have a lot of hope for the future and give a great deal of thanks for the dedication of all those who work so hard for lung cancer patients.”

“I hope that every Canadian province and territory adopts an organized, regular early screening program. We do it for breast, and colon cancer, so why not lung cancer? What’s more, early screening, detection, and treatment of lung cancer saves money in the long run”

-Debi Lascelle
GETTING TO A DIAGNOSIS
#ITMIGHTBECANCER

Debi Lascelle was diagnosed and treated as part of a study. However, as with all patients who are being investigated for lung cancer, there is considerable anxiety involved in “the wait,” “the wait” for further imaging, tests, and biopsies, and then “the wait” for the results. Anxiety levels correlate with “the wait” and increase as wait times escalate.

Rapid-diagnosis assessment programs (RDP) or diagnostic-assessment programs (DAP) can streamline the diagnostic process, help inform patients, and provide support. They help standardize how tests — for example, biopsies and diagnostic scans — are performed, leading to clearer and more comprehensive results. Importantly for patients, the RPD/DAP acts as a guide that helps them navigate the system and reduces “the wait.”

For instance, 59% of individuals suspected of having lung/thoracic cancer who were assessed through one of Ontario’s lung/thoracic RPD/DAPs were diagnosed within the 28-day target following a referral from their primary care providers or other healthcare professionals. This is moving closer to Cancer Care Ontario’s target of 65 percent.13 Yet despite proven effectiveness, RPD/DAPs are limited in some provinces such as British Columbia and Quebec.

LUNG CANCER CANADA BELIEVES

Rapid-diagnosis assessment programs (RDP) or diagnostic-assessment programs (DAP) are critical to efficiently assessing and diagnosing patients. They also provide psychosocial support to patients and help them navigate the healthcare system as they are being assessed. These represent best practices and should be supported across the provinces and territories.

In all cases, Lung Cancer Canada calls for better patient education and engagement through shared discussions and decision-making right from the diagnostic process, which would help foster better participation and improve navigation and patient satisfaction.
A positive diagnosis is just the start of the journey. Today, lung cancer treatment is very much driven by molecular pathologies: the presence or absence of molecular “signatures” in a patient’s lung cancer cells can determine oral targeted therapies versus intravenous treatments, chemotherapy versus immunotherapy, or even different combinations. The importance of molecular testing, which allows for a more personalized treatment, cannot be overemphasized. Standard practices in most provinces are individual sequential-tissue-based tests. However, this uses more tissue, which may limit the number of tests that can be run. There may also be a need for re-biopsy if there was not enough tissue in the original sample to run all the necessary tests. A more efficient methodology is to use a broader panel next-generation sequencing (NGS) assay, which can evaluate all current and emerging biomarkers with a single test. Regardless of the testing methodology, wait times for test results need to be clearly communicated to patients in order to increase awareness and reduce anxiety.

Dr Xu comments, “this is complex science and we are navigating our way through, making note of the successes and failures to advance our understanding. The Canadian PD-L1 22C3 Quality Validation Project is currently taking place in more than a dozen sites across Canada, with the purpose of standardizing a non-kit based assay for PD-L1 expression. This kind of research can be a game-changer.”

Nivolumab and pembrolizumab are two anti-PD-1 antibodies that are approved after failure of conventional chemotherapy for advanced NSCLC in Canada. Nivolumab can be prescribed without biomarker testing for PD-L1 expression. Pembrolizumab is limited to patients with PD-L1-positive tumours. Pembrolizumab has also shown improved efficacy compared with platinum doublet in patients who are treatment-naïve with tumours expressing PD-L1 in 50% of tumour cells or more and is approved by Health Canada.4

The Expert Committee of thoracic oncology experts feels that PD-L1 testing should be readily available at the time of diagnosis of both non-squamous and squamous NSCLC to allow for rapid initiation of pembrolizumab to eligible patients.5 Health Canada approved pembrolizumab in the first-line setting in advanced NSCLC.

LUNG CANCER CANADA BELIEVES

Molecular testing is critical to matching patients to appropriate treatments, leading to improved patient outcomes. New technologies such as NGS should be continuously explored so they can become a cost-effective and efficient standard of care.

Regardless of the testing mechanism, Lung Cancer Canada believes that patients should be educated about the testing process, including the wait time for the results and the meaning of the outcomes in order to increase patients’ engagement and understanding of their cancers.
LAURA
Faces of Lung Cancer Caregiver Story

Navigating the healthcare system can be daunting for someone with lung cancer, or any disease for that matter, but it also poses challenges for a patient’s caregiver. Laura knows that all too well now and during the past few years acting as an advocate for Michelle, her 65-year-old mother.

Late 2014 in Montreal, Michelle consulted her doctor about a persistent cold that wouldn’t go away. The doctor felt Michelle, who was a smoker, had pneumonia, but also thought she might have a much bigger problem. X-rays and scans were called for, then a biopsy. Laura’s mother had limited-stage small cell lung cancer (SCLC) affecting one lung and adjacent lymph nodes.

Laura says her experience felt like being in a nightmare and you can’t wake up. While at the hospital in the spring of 2015 for their appointment to find out the diagnosis, they were handed Michelle’s medical file. During the four hours they waited to see the doctor, they read the diagnosis for themselves. To find this out by reading her mother’s medical file rather than hearing it from her doctor was particularly crushing. However, Michelle and Laura’s voyage through the uncertain seas of lung cancer was only just beginning.

Language differences can play a role in complicating navigation. Laura speaks French, but her mother is more comfortable using English. Navigating the system when not in your first language proved too onerous, so they switched to an English-language hospital. However, the waiting list for scans there was too lengthy and eventually they transferred back to a French hospital, whose services were much faster.

Canada is now so multi-cultural that language barriers are common, and can cause stress and anxiety when trying to understand a new diagnosis and navigate through the system.

Michelle underwent standard treatment for SCLC in 2015. She stopped chemotherapy and radiation that year and had her last scan in the fall of 2016, which revealed that the cancer was gone.

In summing up her own experience as a caregiver and her mother's involvement with the health system, Laura says more emotional and mental support is needed for patients. When it comes to her mother, she says some of the issues that need to be addressed for all patients include language barriers, long wait times, inefficient scheduling, communication breakdowns, deficient integration of healthcare between the different medical specialties, and a lack of empathy. She also stresses the need for more training for health professionals so that patients will feel that the people and system are there to work for them.

Through all the process of her mother’s care, Laura has often been emotionally drained and has felt that she was tilting in vain at windmills. However, she adds, “My mother lives with me now and is doing okay. Next year it’ll be five years since her diagnosis.”

Laura knows that’s really something … like winning a lottery.
Healthcare administration is a provincial responsibility. Each province has its own economy and outlook, which differ across the country. Geographical and population size differences also play a role, and the proportional access to specialist cancer centres also varies across provinces. Therefore, this means that cancer infrastructure and resources are not equal across Canada, which places further challenges not just on programs such as screening and rapid assessment, but also on the delivery of core services.

For example, PET scanners — a crucial test used in the initial diagnosis of lung cancer — are not available in Yukon, Prince Edward Island, and Newfoundland and Labrador. Sites for stereotactic body radiation therapy (SBRT), cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells in a certain area while minimizing damage to healthy tissue, is not available in Newfoundland and Labrador or the territories. While surgical procedures, including thoracic surgery, video-assisted thoracic surgery, and endobronchial ultrasound (EBUS), are available in many Canadian provinces, there are gaps in terms of wait times and the need to travel for certain procedures.

Lung cancer patients living in Prince Edward Island and the territories routinely travel out of province, since none of the above-mentioned surgical procedures are available for them where they live.

Differences between provinces are just one aspect of care. According to a 2014 Canadian Partnership Against Cancer report, Canadians in rural and remote areas have a higher incidence of lung cancer compared to those in urban areas. While reasons may be due in part to differences in smoking rates in less-urban communities, people in rural and remote areas may also have harder access to screening, diagnosis, and treatment services.

Many lung cancer management options available in big and medium-size cities in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec are limited or not available in the remote northern areas of the same provinces or in Yukon, the Northwest Territories, and Nunavut.

Dr Silvana Spadafora, a medical oncologist at the Sault Area Hospital in Sault Ste. Marie, Ontario, maintains that there is a need for access to specialists, diagnostic techniques, and newer treatments in remote sites. Such access would substantially reduce travel to urban sites and lessen the burden on caregivers, since travel can take as long as six to 10 hours and much longer in the winter months. Furthermore, many Canadians in rural areas earn much less money than those in cities, which can also have a huge impact on patients and their caregivers. Travel and associated costs play a significant role in patients’ acceptance or denial of treatment, increased stress, and financial burdens.

A healthcare partnership between the Northwest Territories and Alberta, as seen in the story of lung cancer survivor Allice Legat that follows, demonstrates what can be accomplished to improve the disparities between the North and South, remote and urban, when it comes to lung cancer.
LUNG CANCER CANADA BELIEVES

Patients need to be treated as close to home as possible while still maintaining excellence. The roles for community hospitals and regional centres of excellence in all provinces need to be better identified. Services such as additional chemotherapy infusion sites within smaller communities can help patients be treated closer to home and decrease wait times, as well as forge stronger linkages between community hospitals and regional centres and foster more intensive employment of electronic imaging and data exchange and consultation.

More intensive employment of electronic imaging, data exchange, and consultation through technologies should be encouraged. Services such as Telehealth should be universally adopted, since they can allow patients to interact remotely with health service providers, who will provide a variety of services that include diagnosis, treatment, education, monitoring, and support.

When travel is required, Lung Cancer Canada calls for better access to transportation travel grants in order to relieve financial and emotional stress.
ALLICE LEGAT
Faces of Lung Cancer Patient Story

For sparsely populated parts of Canada, access to specialized healthcare can be very difficult. With a population of just over 44,000 and 1.3 million square kilometres, the Northwest Territories (NWT) has had to develop innovative ways to serve the few people scattered over its vast geography. Allice, a practicing anthropologist and writer, lives in Yellowknife, the territory’s capital. Home to about 20,000 citizens, it’s located 1,500 kilometres north of Edmonton, Alberta.

As early as 2013, she noticed she was feeling more tired than usual but put it down to age and asthma that become more aggravated by huge forest fires occurring in 2014. By late fall 2017, her tiredness had become overwhelming. Then, in January 2018, she developed a nasty case of pink eye and was told at the eye clinic to follow up with a doctor if it didn’t clear up with the drops that were prescribed.

She did just that a month later, and the doctor detected a rattle in her lungs. Allice suggested it was asthma, while the doctor suspected pneumonia, but it was neither; she had a tumour. Allice was sent to Edmonton for an MRI and then a biopsy. By the spring of 2018, her diagnosis was confirmed as inoperable stage IV non-small cell adenocarcinoma with a tumour in the upper lobe of her right lung that had metastasized to right-sided pleura. Despite minimal smoking when she was young, there were no driver mutations identified in her tumour or in the blood, based on the Foundation One testing. Allice stresses that there are many factors that have been implicated in causing lung cancer in addition to smoking. These include radon gas, which is implicated in up to 15 percent of lung cancer deaths per year, and second-hand smoke. In May 2018, she was able to participate in a clinical trial of both chemotherapy and immunotherapy. Currently, Allice is in the maintenance stage and has an immunotherapy infusion every four weeks.

When asked about the travel program, Allice says, “Amazing. I think it’s great We have access to good care even though we don’t have specialists in the NWT. That doesn’t mean there couldn’t be improvements, though. It seems that people in the smaller communities have more difficulty working through the health system, as there seems to be inconsistencies concerning approval for patient escorts.”

Asked how she feels now after a year and a half, Allice says her treatment shrank her tumour and it has been stable for several months. The oncologists hope that her stage IV lung cancer will become a chronic disease rather than a killer. “It really is a breakthrough that I can now walk up hills I couldn’t walk up three years ago. And, more importantly, I stay up past 8:00 p.m. and at times even dance!”

“Moral support from the staff at Lung Cancer Canada, family, friends, and my oncological team,” Allice insists, “have been extremely important to me for feeling positive. We have a women’s group for cancer patients, my son and daughter-in-law are in Yellowknife, and I have friends who want to support my healing by escorting me to appointments in Edmonton and by sharing country food they harvest”

-Allice Legat
While this report has focused on interprovincial differences and geographic differences, it is important to also mention areas that Canada in general can improve on.

As an example, “pleural effusion” is a common complication of lung cancer in which liquid gathers outside the lung, squeezing it and leading to difficulty in breathing or shortness of breath that requires specialized care. Malignant effusion clinics, which help coordinate and provide such care including programs that drain the fluid in a patient’s own home, are limited across the country.

Additionally, psychosocial support and early access to palliative care are areas that all provinces in Canada can improve access to. There is solid evidence that earlier access results in better patient outcomes. When palliative care turns into end-of-life care, the wishes of patients, whether at home or in the hospital, should be provided through provincial support.

As our population ages, it is also important to understand the needs of Canada’s seniors, to recognize that the biggest risk factor for cancer is age, and to appreciate that Canadians are aging. According to Dr David Dawe, a medical oncologist at CancerCare Manitoba, there is a need for more comprehensive evaluations of seniors to better identify those who are well enough to benefit from certain treatment modalities, those who currently may be undertreated or not treated at all, and also to identify the patients who are currently being offered aggressive treatments but may be too frail to handle the side effects.

An ideal model of care would be one where fit, older patients have equal opportunities to be considered for treatments as well as have better established mechanisms for determining those who are frail or vulnerable to frailty in order to tailor their treatments to their bodies’ capabilities. The number of seniors is expected to increase into the early 2030s, which means that a model of care that includes better consideration for this group of patients is crucial.

Canada is a big country, and we need to take care of our population. It is a social responsibility to ensure that no matter where you live, you have adequate access to needed healthcare services. Innovations, leadership, and collaboration among provinces are key to sharing resources to ensure timely and appropriate treatments. Patients such as Alice, Debi, and Michelle have had #HopeRealized. Improving on access to services will allow others to do the same.
### Table 3 – Provincial Access to Lung Cancer Health in Canada

<table>
<thead>
<tr>
<th>Screening</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NB</th>
<th>NL</th>
<th>NS</th>
<th>ON*</th>
<th>PE</th>
<th>QC</th>
<th>SK</th>
<th>NT</th>
<th>NU</th>
<th>NT</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAPID-DIAGNOSIS ASSESSMENT PROGRAM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXT-GENERATION SEQUENCING PANEL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PET SCANNERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Diagnosis**

<table>
<thead>
<tr>
<th>INDIVIDUAL MOLECULAR TESTING</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NB</th>
<th>NL</th>
<th>NS</th>
<th>ON*</th>
<th>PE</th>
<th>QC</th>
<th>SK</th>
<th>NT</th>
<th>NU</th>
<th>NT</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROS1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-L1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PET SCANNERS**

<table>
<thead>
<tr>
<th>PET SCANNERS</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NB</th>
<th>NL</th>
<th>NS</th>
<th>ON*</th>
<th>PE</th>
<th>QC</th>
<th>SK</th>
<th>NT</th>
<th>NU</th>
<th>NT</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET SCANNERS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Treatment**

<table>
<thead>
<tr>
<th>THORACIC SURGERY</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NB</th>
<th>NL</th>
<th>NS</th>
<th>ON*</th>
<th>PE</th>
<th>QC</th>
<th>SK</th>
<th>NT</th>
<th>NU</th>
<th>NT</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIDEO-ASSISTED THORACOSCOPY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ENDOBRONCHIAL ULTRASOUND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RADIAL PROBE ENDOBRONCHIAL ULTRASOUND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MALIGNANT EFFUSION CLINIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STEREOTACTIC BODY RADIATION THERAPY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHEST</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAIN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RADIOFREQUENCY ABLATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAL TAKE-HOME CANCER MEDICATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROVINCIAL REGIONAL CANCER CENTRES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADDITIONAL CHEMOTHERAPY INFUSION SITES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Support programs**

<table>
<thead>
<tr>
<th>NICOTINE-REPLACEMENT PROGRAM</th>
<th>AB</th>
<th>BC</th>
<th>MB</th>
<th>NB</th>
<th>NL</th>
<th>NS</th>
<th>ON*</th>
<th>PE</th>
<th>QC</th>
<th>SK</th>
<th>NT</th>
<th>NU</th>
<th>NT</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMOKING-CESSATION SUPPORT/CLINICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPECIALIST PALLIATIVE CARE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>END-OF-LIFE CARE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOME</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IN-PATIENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In Northern Ontario, certain services are different from the rest of the province. For instance, screening, rapid-diagnosis assessment programs, and malignant effusion clinics are not available; limited diagnostic ability on-site for thoracic surgery (otherwise in Sudbury); next-generation sequencing panels only from the industry upon request; smoking-cessation support and clinics through public health; and nicotine-replacement programs publicly funded if there is no third-party payer.
PART 3
WHO PAYS FOR CANCER?
THE SHAPE OF DRUG FUNDING IN CANADA

#HOPEINFUNDING

For Anne Marie Cerato, access to new treatments were key to being able to celebrate 10 years of living with lung cancer. The five-year survival rate for lung cancer in Canada, which remained fundamentally unchanged for years, rose to 19 percent in statistics reported in 2019.\(^1\) This has been in large part due to new treatments that have become available. Yet access to these treatments in Canada is still challenging.

As in previous years, Lung Cancer Canada provides tables detailing access to lung cancer drugs in our country, documenting the time from U.S. Federal Drug Administration (FDA) approval to Health Canada approval, the time it takes to receive positive funding recommendations from pCODR or INESSS (Quebec’s Institut national d’excellence en santé et en services sociaux), and the time to provincial listing. The FDA was chosen as a baseline because it is often the first regulatory body to approve new treatments.

One part of these differences is due to when manufacturers choose to make an application for approval to Health Canada. However, it can be seen in Table 4 that in many cases the difference between FDA approval and Health Canada approval is relatively short. In one case, Health Canada’s approval even came before FDA approval.

Most of the time noted in the tables that follow is due to our system and process. It is important to remember that Canada and the United States have fundamentally different healthcare systems. Whereas the U.S. system is primarily private-insurance-driven, Canada has a public healthcare system and thus has a system after Health Canada approval to ensure responsible use of public funds.

This Health Technology Assessment (HTA) process starts with pCODR or INESSS to assess the value of a drug: how well does it work compared to the standard treatment, does it meet patient values, what do clinicians feel about the new treatment. Following a positive pCODR or INESSS recommendation, confidential pricing negotiations begin and are conducted between the Pan-Canadian Pharmaceutical Alliance (PCPA) and manufacturers. Once a price has been agreed upon, the provinces then decide how and when to incorporate it into their provincial budgets.
As lung cancer treatment has evolved, it is the HTA’s more traditional definition of benefit and then value that is creating barriers to access. Lung cancer treatments are the leaders in targeted therapies, which has changed the paradigm of cancer treatment. Due to targeted therapies’ ability to focus on specific molecular signatures in lung cancer cells, they have drastically increased response rates over traditional chemotherapy.

Many targeted therapies are approved by Health Canada with phase 2 data (these are usually smaller studies and not necessarily a direct comparison with the existing treatment). However, most targeted therapies submitted to pCODR using phase 2 data have received negative funding recommendations. All treatments that have been tested with phase 3 trials (larger, more expensive studies comparing the new drug with the existing treatment) have had to resubmit with phase 3 trial results rather than being able to use compelling phase 2 results.

Even more alarming, specific targeted therapies only serve very small subsets of lung cancer patients, so phase 3 trials are often not possible. This is the case with dabrafenib and trametinib, targeted therapies for BRAF positive patients, who make up less than 1 percent of the lung cancer population. This has severely limited access for Canadian BRAF positive lung cancer patients.

On the other hand, part of the funding challenge is due to the cost of medications. According to the 2017 annual report of the Patented Medicines Pricing Review Board (PMPRB), from 2006 to 2017, the 28-day average treatment cost for oncology medicines increased by 82 percent, rising from $3,867 to $7,057. With more novel medications to come, these costs are projected to increase, which poses a significant challenge for a publicly funded system.

When medicines are not publicly covered and patients have no, or are denied, private insurance coverage, how can patients pay for the life-saving medicines they need?

For some people like Rachel McPhedran’s father, Andrew, lung cancer has turned into GoFundMe disease.

---

**Figure 2 — Drug Approval and Access Process in Canada**

Health Canada → CDR/pCODR/INESS → pan-Canadian Pharmaceutical Alliance (pCPA) → Ministry of Health
ANDREW AND RACHEL MCPHEDRAN
Faces of Lung Cancer Patient and Caregiver Story

It started with a nagging backache. Andrew, who lives in Ottawa, was pretty active and used to back strains, so at first he dismissed the pain. But it got worse and worse. His doctor thought it might be an inguinal hernia, so he had an ultrasound. When the pain became so bad that he couldn’t walk, a CT scan was ordered, followed by more tests. Then, in early December 2018, he was diagnosed with stage IV non-small cell lung cancer. As a lifelong non-smoker, 54-year-old Andrew was astonished.

Molecular testing in January 2019 determined that his cancer was positive for an epidermal growth factor receptor (EGFR) mutation. His doctors recommended osimertinib (Tagrisso®) as a first-line therapy because it is highly effective for EGFR+ tumours, has fewer side effects than older-generation EGFR inhibitors like afatinib, and leads to better life expectancy and quality of life for patients.

There was a catch, though. Although osimertinib has been approved by Health Canada and the pan-Canadian Oncology Drug Review, it isn’t publicly funded by any province as a first-line treatment, though it is funded as a second-line drug in all provinces except Newfoundland and Labrador, Nova Scotia, and Prince Edward Island. So without access to a clinical study or private insurance coverage, osimertinib costs as much as $9,000 per month. Andrew says that when he discovered that osimertinib would cost so much, he panicked.

But his daughter, Rachel, heard from a friend about GoFundMe campaigns that had raised funds for cancer drugs, so she thought they should try it. The family was very fortunate to have friends who were willing, generous, and able to donate, and things took off from there. The GoFundMe campaign has been very successful, and Andrew has been on osimertinib for the past nine months, the tumours are shrinking, and he is doing well on the treatment.

Patients and caregivers in Canada, including Rachel, are petitioning AstraZeneca, the manufacturer of osimertinib, and provincial governments to find ways to make the drug publicly funded so that other patients won’t have to resort to crowdfunding campaigns to fund their treatments.

As for Andrew, who is 55 now, he says he hopes to see 56 “with a little bit of effort and a little bit of good luck and all those things that come into play”.

Lung cancer treatment should not be a GoFundMe campaign. Andrew was very fortunate that he was able to receive the treatment his physician felt fit best. But what happens if he is “really fortunate” and the drug works for so long that the GoFundMe dollars run out?

However, others, who are not able to find funding for treatments, are faced with difficult choices. What follows is Angus Pratt’s story.
ANGUS PRATT
Faces of Lung Cancer Patient Story

Born in Scotland and raised in Saskatchewan, Angus is a 61-year-old freelance web developer and first-aid worker who now lives in Surrey, British Columbia. His mother died of breast cancer when he was in his late teens and his brother was diagnosed with the same disease 10 years ago. In early 2018, Angus says he knew he had something in his right breast but didn’t do anything about it for a while. Then he finally went to see his doctor, who confirmed that he did have a lump in his right breast and one in the other breast, too.

An X-ray and ultrasound were scheduled, and the morning after, he was informed that a biopsy was necessary. Ten days later, he was told he had intraductal carcinoma of the breasts. As standard procedure, further CT and bone scans were done and a tumour was discovered in one lung, a shock to him since he had never smoked. This was followed with another biopsy, which determined that he had stage IIIC non-small cell adenocarcinoma. Subsequent molecular testing indicated that he had the epidermal growth factor receptor (EGFR) mutation.

The lung cancer was more urgent, so treatment for the breast cancer was put aside as he underwent six cycles of chemotherapy and 30 days of radiation. Six weeks after that, he had a bilateral mastectomy for his breast cancer. In September 2018, he was put on immunotherapy for the lung cancer. However, it didn’t halt the growth of the tumour and his cancer progressed to stage IV by March 2019.

Angus’s doctor recommended that he, like Andrew McPhedran, take the new drug, osimertinib (Tagrisso®).

But, as described in Andrew’s story, the medication isn’t publicly funded as a first-line treatment in any province in the country, despite being recommended by the pan-Canadian Oncology Drug Review. So, as a second option, Angus began taking afatinib (Geotrif®), which he’s still on. Even though the afatinib has been effective so far, it has more side effects than osimertinib — weekly diarrhea, a nasty red eczema rash and pimples, slight cognitive lapses — and thus reduces his quality of life.

When asked about the lack of public funding for certain essential lung cancer drugs, Angus says, “Yeah, it’s frustrating for me, and no doubt other patients. Governments and drug companies need to talk more to each other and work hard to resolve the pricing and funding issues. I know it’s a numbers game, but people are suffering due to the intransigence of both parties.”

A widower with three sons now after his wife, Yvette, passed away from pancreatic cancer in November 2018, Angus has endured a great deal since his original diagnosis more than a year ago. Nevertheless, he’s recertifying as a first-aid attendant and enjoys triumphs when they occur. A case in point is when he got the all-clear on a recent brain scan as well as the news that nodules in his left lung had shrunk or even disappeared. “I hadn’t realized how much everything had been weighing on me. I’m a Scotsman, pretty stoic, and don’t let things get to me too much, but when I got the good news, there was a fist pump and I was a pretty happy boy. It was a moment when it was working. It was exciting.”
Andrew and Angus both hoped to access a newer medication that, while having completed the HTA process, is still not funded by provinces. However, even in cases where the HTA process has been completed and provinces have listed the treatment, access can still be challenging.

Patients prescribed an oral take-home medication who live in Canada’s western provinces are 100 percent covered by their provinces. Patients in Ontario and Atlantic Canada are not. For patients in these provinces, cancer treatments administered in hospitals are fully covered and those taken at home are not. Applications to special programs for further coverage throw up administrative barriers and cause significant delays to access. Yet, according to Cancer-Certainty, a coalition of Canadian patient groups, cancer health charities, and caregiver organizations working with oncologists and cancer-care professionals to improve the affordability and accessibility of cancer treatment, the additional cost to fully cover these treatments is small. For example, in Ontario it is estimated that an investment of $28 to $93 million, or roughly 1 percent of Ontario’s total 2012 drug budget, will ensure all patients in Ontario have access to take-home cancer medications. The investment is also estimated to lead to at least a 17 percent reduction in overall chemotherapy unit costs. The same holds true, proportionally, for Newfoundland and Labrador, New Brunswick, and Prince Edward Island.18

How does the lung cancer community move forward and what happens from here?

**LUNG CANCER CANADA BELIEVES**

A dialogue and collaboration must occur between all stakeholders, including patients, clinicians, manufacturers, and HTA bodies, to discuss ways to modernize Canada’s public system in order to improve access and affordability.

Personalized medicines are a key component to treating lung cancer, and as treatments include more targets, lung cancer patients will be subset into smaller and smaller populations.

Traditional phase 3 studies may mean patients have unnecessary wait times or may not even have access to the medicines they need. Explorations of new funding models, such as those where manufacturers risk-share with the funders, are critical. Time-limited funding models and re-evaluation based on additional clinical or real-world evidence should also be explored. Oral medications need to be fully covered across the country.

Treatment of patients at home results in savings to the system. These savings, and those realized through new funding models, need to be reinvested back into the healthcare system so that access to cancer services and treatments throughout the cancer journey can be equal and timely through all regions and populations in Canada.

National pharmacare, with comprehensive, universal and equitable access to drugs across Canada, is called for by Lung Cancer Canada. For all lung cancer patients, access is key to #HopeRealized.
### Table 4 — Date of FDA Approval to Health Canada Approval

<table>
<thead>
<tr>
<th>DRUG Generic name brand name</th>
<th>INDICATION</th>
<th>FDA APPROVAL DATE</th>
<th>HEALTH CANADA APPROVAL DATE</th>
<th>pCODR Status</th>
<th>Phase Data Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>alectinib (Alecensaro®)</td>
<td>As monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or are intolerant to crizotinib until loss of clinical benefit.</td>
<td>December 11, 2015</td>
<td>September 29, 2016</td>
<td>Final Recommendation March 29, 2018: Recommended pending cost-effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>alectinib (Alecensaro®)</td>
<td>For the first-line treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced or metastatic NSCLC.</td>
<td>November 6, 2017</td>
<td>June 11, 2018</td>
<td>Final Recommendation July 25, 2018: Recommended pending cost-effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>aezolizumab (Tecentriq®)</td>
<td>For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide.</td>
<td>March 18, 2019</td>
<td>August 8, 2019</td>
<td>Initial Recommendation October 3, 2019: Not recommended</td>
<td>3</td>
</tr>
<tr>
<td>aezolizumab (Tecentriq®)</td>
<td>For the treatment of patients with locally advanced or metastatic NSCLC who have progressed on or after systemic chemotherapy until loss of clinical benefit.</td>
<td>October 18, 2016</td>
<td>April 6, 2018</td>
<td>Final Recommendation June 20, 2018: Recommended pending cost-effectiveness</td>
<td>2 + 3</td>
</tr>
<tr>
<td>brigatinib (Alunbrig®)</td>
<td>For the treatment of adult patients with ALK positive metastatic NSCLC who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).</td>
<td>April 28, 2017</td>
<td>July 26, 2018</td>
<td>Final Recommendation August 1, 2019: Not Recommended</td>
<td>2</td>
</tr>
<tr>
<td>ceritinib (Zykadia®)</td>
<td>For treatment as monotherapy in patients with ALK positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.</td>
<td>April 29, 2014</td>
<td>March 27, 2015</td>
<td>Final Recommendation December 3, 2015: Not Recommended</td>
<td>2</td>
</tr>
<tr>
<td>ceritinib (Zykadia®)</td>
<td>For treatment as monotherapy in patients with ALK positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to crizotinib.</td>
<td>April 29, 2014</td>
<td>March 27, 2015</td>
<td>Final Recommendation March 21, 2017: Recommended pending cost-effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>crizotinib (Xalkori®)</td>
<td>As monotherapy for use in patients with ALK positive advanced (not amenable to curative therapy) or metastatic NSCLC.</td>
<td>August 26, 2011</td>
<td>April 25, 2012</td>
<td>Final Recommendation May 2, 2013: Recommended pending cost-effectiveness*</td>
<td>3</td>
</tr>
</tbody>
</table>

As of October 10, 2019
## Continued... Table 4 — Date of FDA Approval to Health Canada Approval

<table>
<thead>
<tr>
<th>DRUG Generic name brand name</th>
<th>INDICATION</th>
<th>FDA APPROVAL DATE</th>
<th>HEALTH CANADA APPROVAL DATE</th>
<th>pCODR Status</th>
<th>Phase Data Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>crizotinib (Xalkori®)</td>
<td>Patients with ALK positive advanced NSCLC.</td>
<td>August 26, 2011</td>
<td>April 25, 2012</td>
<td>Final Recommendation July 21, 2015: Recommended pending cost- effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>Resubmission 1st line</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>crizotinib (Xalkori®)</td>
<td>As a single agent as first-line treatment for patients with ROS1 positive advanced NSCLC.</td>
<td>March 11, 2016</td>
<td>August 28, 2017</td>
<td>Final Recommendation May 23, 2019: Recommended pending cost- effectiveness</td>
<td>1 + 2</td>
</tr>
<tr>
<td>ROS1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dabrafenib (Tafinlar®) +</td>
<td>In combination for the treatment of patients with metastatic NSCLC with a BRAF V600 mutation.</td>
<td>June 22, 2017</td>
<td>May 18, 2018 May 16, 2017</td>
<td>Final Recommendation November 2, 2017: Not Recommended (previously treated with chemotherapy)</td>
<td>2</td>
</tr>
<tr>
<td>trametinib (Mekinist®) 2nd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>line</td>
<td></td>
<td></td>
<td>(previously treated with chemotherapy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dacarbostinib (Vizimpro®)</td>
<td>For the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR activating mutations.</td>
<td>September 27, 2018</td>
<td>February 26, 2019</td>
<td>Final Recommendation May 31, 2019: Conditional Recommendation pending cost- effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>durvalumab (IMFINZI®) Stage III unresectable NSCLC</td>
<td>For the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy (CRT), for follow-up to a maximum of 12 months.</td>
<td>February 16, 2018</td>
<td>May 4, 2018 NOC/c August 23, 2019 NOC</td>
<td>Final Recommendation May 3, 2019: Recommended pending cost- effectiveness</td>
<td>3</td>
</tr>
<tr>
<td>entrectinib (TBD)</td>
<td>For the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion positive, locally advanced or metastatic solid tumours in adult and pediatric patients.</td>
<td>August 15, 2019</td>
<td>Under Review</td>
<td></td>
<td>1 + 2</td>
</tr>
<tr>
<td>lorlatinib (Vitrakvi®)</td>
<td>For the treatment of adult and pediatric patients with locally advanced or metastatic solid tumours harbouring a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.</td>
<td>November 26, 2018</td>
<td>July 10, 2018</td>
<td>Initial Recommendation August 29, 2019: Not Recommended for lung cancer</td>
<td>1 + 2</td>
</tr>
<tr>
<td>lorlatinib (Lorbrena®)</td>
<td>For the treatment of adult patients with ALK positive metastatic NSCLC who have progressed on crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.</td>
<td>November 2, 2018</td>
<td>February 22, 2018 NOC/c</td>
<td>Under Review</td>
<td>2</td>
</tr>
<tr>
<td>nivolumab (Opdivo®)</td>
<td>For the treatment of patients with metastatic NSCLC whose tumours express PD-L1 (as determined by a validated test) and who have disease progression on or after platinum-containing chemotherapy</td>
<td>March 4, 2015</td>
<td>February 26, 2016</td>
<td>Final Recommendation June 3, 2016</td>
<td>3</td>
</tr>
</tbody>
</table>
## Table 4 — Date of FDA Approval to Health Canada Approval

<table>
<thead>
<tr>
<th>DRUG Generic name (brand name)</th>
<th>INDICATION</th>
<th>FDA APPROVAL DATE</th>
<th>HEALTH CANADA APPROVAL DATE</th>
<th>pCODR Status</th>
<th>Phase Data Used</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>osimertinib</strong> (Tagrisso®) 2nd line</td>
<td>For the treatment of patients with locally advanced or metastatic EGFR T790M mutation positive NSCLC who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy</td>
<td>November 13, 2015</td>
<td>July 5, 2016</td>
<td>Final Recommendation May 4, 2017: Recommended pending cost-effectiveness</td>
<td>2 (initial NOC/c based on phase 2 data) pCODR submission based on phase 3 data</td>
</tr>
<tr>
<td><strong>osimertinib</strong> (Tagrisso®) 1st line</td>
<td>For the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR mutations.</td>
<td>April 18, 2018</td>
<td>July 10, 2018</td>
<td>Final Recommendation January 4, 2019: Recommended pending cost-effectiveness</td>
<td>3</td>
</tr>
<tr>
<td><strong>pembrolizumab</strong> (Keytruda®) 2nd line</td>
<td>For the treatment of patients with metastatic NSCLC whose tumours express programmed death-ligand 1 (PD-L1) (as determined by a validated test) and who have disease progression on or after platinum-containing chemotherapy.</td>
<td>September 4, 2014</td>
<td>April 15, 2016</td>
<td>Final Recommendation November 3, 2016: Conditional Recommendation based on cost-effectiveness</td>
<td>2/3</td>
</tr>
<tr>
<td><strong>pembrolizumab</strong> (Keytruda®)</td>
<td>In combination with pemetrexed and platinum chemotherapy, for the treatment of metastatic non-squamous NSCLC, in adults with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.</td>
<td>May 12, 2017</td>
<td>March 13, 2019</td>
<td>Final Recommendation May 31, 2019: Recommended pending cost-effectiveness</td>
<td>2/3</td>
</tr>
<tr>
<td><strong>pembrolizumab</strong> (Keytruda®)</td>
<td>For the treatment of patients with metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel, in adults with no prior systemic chemotherapy treatment for metastatic NSCLC</td>
<td>October 30, 2018</td>
<td>July 4, 2019</td>
<td>Under Review</td>
<td>2/3</td>
</tr>
<tr>
<td><strong>pemetrexed</strong> (Alimta®) 2nd line</td>
<td>For maintenance following first-line pemetrexed and cisplatin for advanced or metastatic non-squamous NSCLC.</td>
<td>July 2, 2009</td>
<td>May 9, 2013</td>
<td>Final Recommendation November 19, 2013: Recommended pending cost-effectiveness</td>
<td>3</td>
</tr>
<tr>
<td><strong>ramucirumab</strong> (Cyramza®) 2nd line</td>
<td>For the treatment of patients with advanced or metastatic NSCLC who progressed on or after platinum-based chemotherapy in combination with docetaxel.</td>
<td>April 21, 2014</td>
<td>July 16, 2015</td>
<td>Closed, not submitted</td>
<td>3</td>
</tr>
</tbody>
</table>

**Notes:**
- ALK = anaplastic lymphoma kinase
- CNS = central nervous system
- EGFR = epidermal growth factor receptor
- NSCLC = non-small cell lung cancer
- TKI = tyrosine kinase inhibitor

As of October 10, 2019
## Table 5 — Date of Provincial Coverage

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>BC</th>
<th>AB</th>
<th>SK</th>
<th>MB</th>
<th>ON</th>
<th>QC</th>
<th>NS</th>
<th>NB</th>
<th>NL</th>
<th>PEI</th>
</tr>
</thead>
<tbody>
<tr>
<td>alectinib</td>
<td>May 1, 2019</td>
<td>Not Funded</td>
<td></td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>alectinib</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>February 11, 2019</td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>atezolizumab</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>February 11, 2019</td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>ceritinib</td>
<td>September 1, 2018</td>
<td>October 30, 2018</td>
<td>August 15, 2018</td>
<td></td>
<td>July 19, 2018</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>November 30, 2018</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>crizotinib (1st line)</td>
<td>December 1, 2015</td>
<td>December 18, 2015</td>
<td>December 28, 2015</td>
<td></td>
<td>December 4, 2015</td>
<td>February 8, 2016</td>
<td>May 2, 2016</td>
<td>April 12, 2016</td>
<td>February 1, 2016</td>
<td>August 1, 2018</td>
</tr>
<tr>
<td>crizotinib (ROS1)</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>durvalumab</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
<td>Not Funded</td>
<td>October 2, 2019</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>osimertinib (1st line)</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>osimertinib (2nd line)</td>
<td>October 1, 2018</td>
<td>November 20, 2018</td>
<td>November 1, 2018</td>
<td></td>
<td>October 18, 2018</td>
<td>November 8, 2018</td>
<td>Not Funded</td>
<td>February 27, 2019</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>pembrolizumab (non-squamous NSCLC)</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>DRUG Generic name</td>
<td>FDA APPROVAL DATE</td>
<td>BC</td>
<td>AB</td>
<td>SK</td>
<td>MB</td>
<td>ON</td>
<td>QC</td>
<td>NS</td>
<td>NB</td>
<td>NL</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>afatinib</td>
<td>July 12, 2013</td>
<td>446</td>
<td>445</td>
<td>430</td>
<td>461</td>
<td>403</td>
<td>1027</td>
<td>535</td>
<td>426</td>
<td>689</td>
</tr>
<tr>
<td>alectinib (1st line)</td>
<td>November 6, 2017</td>
<td>541</td>
<td>Not Funded</td>
<td>462</td>
<td>571</td>
<td>Not Funded</td>
<td>452</td>
<td>Not Funded</td>
<td>556</td>
<td>Not Funded</td>
</tr>
<tr>
<td>alectinib (2nd line)</td>
<td>December 11, 2015</td>
<td>1,237</td>
<td>Not Funded</td>
<td>1,158</td>
<td>1,267</td>
<td>Not Funded</td>
<td>1,148</td>
<td>Not Funded</td>
<td>1,252</td>
<td>Not Funded</td>
</tr>
<tr>
<td>alectinib (2nd line)</td>
<td>December 11, 2015</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>846</td>
<td>848</td>
<td>Not Funded</td>
<td>838</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>ceritinib</td>
<td>April 29, 2014</td>
<td>1,586</td>
<td>1,645</td>
<td>1,569</td>
<td>1,542</td>
<td>1,626</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>1,676</td>
<td>Not Funded</td>
</tr>
<tr>
<td>crizotinib (1st line)</td>
<td>August 26, 2011</td>
<td>1,558</td>
<td>1,575</td>
<td>1,585</td>
<td>1,606</td>
<td>1,561</td>
<td>1,627</td>
<td>1,711</td>
<td>1,691</td>
<td>1,620</td>
</tr>
<tr>
<td>crizotinib (2nd line)</td>
<td>August 26, 2011</td>
<td>918</td>
<td>797</td>
<td>769</td>
<td>784</td>
<td>768</td>
<td>893</td>
<td>828</td>
<td>805</td>
<td>949</td>
</tr>
<tr>
<td>crizotinib (ROS1)</td>
<td>March 11, 2016</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>durvalumab</td>
<td>February 16, 2018</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>593</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>nivolumab (2nd line)</td>
<td>March 4, 2015</td>
<td>728</td>
<td>761</td>
<td>750</td>
<td>740</td>
<td>748</td>
<td>749</td>
<td>759</td>
<td>790</td>
<td>883</td>
</tr>
<tr>
<td>osimertinib (1st line)</td>
<td>April 18, 2018</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>osimertinib (2nd line)</td>
<td>November 13, 2015</td>
<td>1,053</td>
<td>1,103</td>
<td>1,084</td>
<td>1,070</td>
<td>1,055</td>
<td>1,091</td>
<td>Not Funded</td>
<td>1,202</td>
<td>Not Funded</td>
</tr>
<tr>
<td>pembrolizumab (1st line)</td>
<td>October 24, 2016</td>
<td>465</td>
<td>480</td>
<td>409</td>
<td>417</td>
<td>450</td>
<td>387</td>
<td>577</td>
<td>555</td>
<td>583</td>
</tr>
<tr>
<td>pembrolizumab (2nd line)</td>
<td>September 4, 2014</td>
<td>1,246</td>
<td>1,261</td>
<td>1,190</td>
<td>1,198</td>
<td>1,231</td>
<td>1,168</td>
<td>1,358</td>
<td>1,336</td>
<td>1,364</td>
</tr>
<tr>
<td>pembrolizumab (non-squamous NSCLC)</td>
<td>May 12, 2017</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>pembrolizumab (2nd line)</td>
<td>May 12, 2017</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
</tr>
<tr>
<td>pembrolizumab (2nd line)</td>
<td>May 12, 2017</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
</tr>
<tr>
<td>pembrolizumab (2nd line)</td>
<td>May 12, 2017</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td>Not Funded</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6 — Number of Days from Date of FDA Approval to Date of Provincial Coverage

As of October 10, 2019
A MESSAGE FROM THE PRESIDENT
#HOPEFORTHEFUTURE

As we come to the end of another decade, it is a good time to review the progress that has been made in lung cancer treatment over the past 10 years while recognizing the challenges ahead at the dawn of a new decade.

Lung cancer remains the most common cancer in Canada. While in 2009 there were 23,400 cases, in 2019 more than 29,000 are anticipated, largely due to the growing and aging Canadian population. But sadly, lung cancer also claims more lives than any other cancer, with around 21,000 deaths projected in 2019. Actually, that isn’t too different from the 20,500 deaths in 2009. While that is a depressing number there are clear signs of progress. The proportion of lung cancer patients surviving five years is actually increasing, from 15% in 2009 to an all-time high of 19 percent in 2019. Slow but real progress!

What must we do to improve on this, and what should our priorities be?

In September 2018, the lung cancer global community came to Toronto for the annual World Conference on Lung Cancer. We learned important information confirming the major role lung cancer screening can play in reducing lung cancer deaths through early detection. Today, half of lung cancer patients have stage IV (incurable) disease when diagnosed, yet with CT scan screening there is the potential to diagnose hundreds and thousands more with earlier-stage disease with a realistic opportunity for cure. Disappointingly, lung cancer screening is not available for most of the Canadian population, while many of our peer nations are introducing programs. At time of writing, limited screening is available only in Alberta, British Columbia, Nova Scotia, Ontario, and Yukon; however, no programs are comprehensive and the future of each remains uncertain.

So with our first priority being access to new screening programs, our second priority is access to new treatments to improve and prolong the lives of lung cancer patients. There have been remarkable advances over the past decade such as the identification of molecular subtypes, and treatments targeting each of those subtypes with tablet medications. This has led to outstanding improvements in quality and quantity of life for those individuals. More recently, the emergence of immunotherapy, drugs that stimulate the body’s own immune system to fight the cancer, has further dramatically altered treatment protocols and improved lives from coast to coast to coast. In my clinical practice, I daily see lives transformed for the better from these treatments.

Our challenge, though, is equitable access to these treatments across all provinces and territories. While we do well at ultimately approving most of these treatments, unfortunately we still see discrepancies in the time taken to approve new drugs in different jurisdictions, and grapple with some bizarre differences between jurisdictions that impact access based on age or the type of drug. Overall, it is still disappointing how long it takes for the regulatory process to be completed. Worryingly, we have also seen problems recently with access to commonly approved and well-established drugs due to manufacturing and distribution challenges. So in some situations we are having problems with our current treatments, let alone fighting for the newest ones.

The 2019 Faces of Lung Cancer Report highlights in more detail some of these challenges, while celebrating the successes we have seen. At Lung Cancer Canada, we are committed to raising awareness, advocating for lung cancer screening and access to treatments, and supporting the tens of thousands of patients and their loved ones facing lung cancer each year.

Please join us in trying to turn lung cancer into a disease of the past.

— Dr Paul Wheatley-Price, President of Lung Cancer Canada
LUNG CANCER CANADA
#LCC

Lung Cancer Canada is a national charitable organization that serves as Canada’s leading resource for lung cancer education, patient support, research and advocacy. Based in Toronto, Ontario, Lung Cancer Canada has a wide reach that includes both regional and pan-Canadian initiatives. Lung Cancer Canada is a member of the Global Lung Cancer Coalition and is the only organization in Canada focused exclusively on lung cancer.

Lung Cancer Canada’s mission is three-fold: 1) to increase public awareness of lung cancer, 2) to support and advocate for lung cancer patients and their families, and 3) to provide educational resources to patients, family members, healthcare professionals, and the general public.

Lung Cancer Canada also offers a variety of resources to educate and support patients and their families. These include: 1) our website, which serves as a trustworthy and timely source of lung cancer information and news; 2) our newsletter, Lung Cancer Connection, which explores topics of interest to the entire lung cancer community; 3) our Resource Library, which allows patients and their families to access specialized information; and 4) our social media presence, as well as the discussion forums and patient stories on our website, which offer lung cancer patients and families the opportunity to connect and offer support to one another.
THE FACES OF LUNG CANCER REPORT FOR 2019

REFERENCES


PHOTO CREDITS

Debi Lascelle - Jeff Fox
Alice Legat - Tessa MacIntosh
Angus Pratt - Evan Pratt
Angus and Yvette Pratt - Delores Carter
Heather Hogan - Lynn Murphy (Reflections Photography)
Ottawa peer group - Joelle Perrier

Cover Page
Alice Legat (Northwest Territories)
Alan Soon (British Columbia)
Lorne Cochrane (Alberta)
Christine Wu (Manitoba)
Heather Hogan (New Brunswick) – Lynn Murphy (Reflection Photography)
LUNG CANCER CANADA BOARD OF DIRECTORS

President
Dr Paul Wheatley-Price
Medical Oncologist
Ottawa Hospital Cancer Centre
Ottawa, ON

Vice President/Treasurer
Maria Amaral
Caregiver Advocate
Toronto, ON

Vice President
Dr Stephanie Snow
Medical Oncologist
QEII Health Sciences Centre
Halifax, NS

Secretary
Sumbul Ali
Sun Life Assurance Co.
Toronto, ON

MEMBERS
Roz Brodsky
Lung Cancer Survivor
Patient Advocate and
Dog Rescuer
Thornhill, ON

Anne Marie Cerato
Lung Cancer Survivor
Patient Advocate
Toronto, ON

Dr Cheryl Ho
Medical Oncologist
BC Cancer Agency
Vancouver, BC

Dr Rosalyn Juergens
Medical Oncologist
Juravinski Cancer Centre
Hamilton, ON

Lorraine Martelli
Nurse Practitioner
Trillium Health Partners
Mississauga, ON

Elizabeth Moreau
Caregiver Advocate
Ottawa, ON

Joel Rubinovich
Chartered Accountant
Toronto, ON

Dr Zhaolin Xu
Pathologist
QEII Health Sciences Centre
Halifax, NS

MEDICAL ADVISORY COMMITTEE

Chair
Dr Rosalyn Juergens
Medical Oncologist
Juravinski Cancer Centre

Members
Dr Normand Blais
Medical Oncologist
Hôpital Notre Dame du CHUM

Dr Nicole Bouchard
Respirologist
Sherbrooke University Hospital

Dr Quincy Chu
Medical Oncologist
Cross Cancer Institute

Dr David Dawe
Medical Oncologist
CancerCare Manitoba

Dr Cheryl Ho
Medical Oncologist
BC Cancer Agency

Dr Diana Ionescu
Pathologist
BC Cancer Agency

Dr Stephen Lam
Respirologist
BC Cancer Agency

Dr Donna Maziak
Thoracic Surgeon
The Ottawa Hospital

Dr David Palma
Medical Oncologist
London Health Sciences Centre

Dr Jeffrey Rothenstein
Medical Oncologist
Lakeridge Health

Dr Stephanie Snow
Medical Oncologist
QEII Health Sciences Centre

Dr Yee Ung
Radiation Oncologist
Sunnybrook Health Sciences Centre

Dr Paul Wheatley-Price
Medical Oncologist
Ottawa Hospital Cancer Centre

Dr Zhaolin Xu
Pathologist
QEII Health Sciences Centre

Dr Sunil Yadav
Medical Oncologist
Saskatoon Cancer Centre
HONORARY BOARD MEMBERS

Catherine Black
Dr Gail E Darling
Dr Peter Ellis
Dr WK (Bill) Evans
Dr Margaret Fitch
Ralph Gouda (Founder)
Dr Michael Johnston
Peter F MacKenzie
Morton Sacks
Dr Frances Shepherd
Dr Yee Ung (Founder)
EK (Ted) Weir
Magdalene Winterhoff (Founder)

ACKNOWLEDGMENTS

Lung Cancer Canada would like to thank the Medical Advisory Committee and other experts for their support in the creation of this report. Special thanks to Dr Paul Wheatley-Price and Dr Silvana Spadafora for their input. To Anne Marie Cerato, Debi Lascelle, Angus Pratt, and Andrew and Rachel McPhedran, thank you for sharing your stories. And to Laura, thank you for sharing Michelle’s story.
Lung Cancer Canada is a national charity and the only one dedicated solely to lung cancer. It relies on donations to offer programs and services, such as this booklet, to patients and their families.

Donations are greatly appreciated and a tax receipt is issued for a donation of $20 or more. Donations can be made online at www.lungcancer canada.ca, or by calling the numbers above.

This report was made possible through the generous support of Amgen Canada, AstraZeneca Canada, Bayer Canada, Bristol-Myers Squibb Canada, Merck Canada, Pfizer Canada, Roche Canada, Takeda Canada, Michael Carroll and Titan Creative. Without your help, this project and endeavour would not have been possible. THANK YOU!

© Lung Cancer Canada 2019.